Sou Hu Wang·2026-02-25 07:25Core Insights - Fosun Pharma's subsidiary, Fosun Wanbang, launched the topical anesthetic, Rize Lin® (Lidocaine/Prilocaine Cream), on Alibaba Health, marking a strategic expansion into the outpatient market [1] - The product has a long-standing global application history and is approved for pain relief in skin punctures and superficial surgical procedures in China since 1998 [1] - The growth of the aesthetic and men's health sectors has led to increased visibility and application of the product in outpatient settings, with it being recommended as a first-line option in guidelines for premature ejaculation [1] Market Performance - The Rize Lin® cream has shown steady growth in both public hospitals and consumer medical markets, with projected sales in public medical institutions exceeding 420 million yuan in 2024 [1] - The total market size for Rize Lin® cream, including applications in aesthetic medicine and premature ejaculation, is expected to surpass 1 billion yuan [1] Regulatory and Academic Support - In 2024, the National Medical Products Administration released technical guidelines for the bioequivalence study of Lidocaine/Prilocaine cream, and the first clinical application consensus for skin surface anesthetics was published [2] - International guidelines from organizations like the European Urological Association have also recommended such compounded creams, providing a robust regulatory and academic framework for Rize Lin® [2] Strategic Collaboration - The partnership with Alibaba Health leverages its platform advantages in digital health services, aiming to reach consumers who prioritize privacy, convenience, and safety [2]